BioCryst Pharmaceuticals
BCRX
103 hedge funds and large institutions have $501M invested in BioCryst Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 25 increasing their positions, 36 reducing their positions, and 10 closing their positions.
101% more call options, than puts
Call options by funds: $972K | Put options by funds: $484K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
18% more capital invested
Capital invested by funds: $425M → $501M (+$76.4M)
0% more funds holding
Funds holding: 103 → 103 (0)
0% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 10
1.81% less ownership
Funds ownership: 90.34% → 88.53% (-1.8%)
31% less repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 36
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$18.9M |
| 2 |
D.E. Shaw & Co
New York
|
+$3.69M |
| 3 |
BlackRock
New York
|
+$1.55M |
| 4 |
VMI
VHCP Management II
New York
|
+$1.34M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$693K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$7.17M |
| 2 |
Millennium Management
New York
|
-$5.48M |
| 3 |
State Street
Boston,
Massachusetts
|
-$4.55M |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$3.72M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$2.18M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
OC
101
Oakworth Capital
Birmingham,
Alabama
| $1K | – | – | – |
|
|
FHA
102
Flagship Harbor Advisors
Boston,
Massachusetts
| $1K | +$1.65K | +300 | New |
|
|
AA
103
ALPS Advisors
Denver,
Colorado
| – | -$630K | -132,021 | Closed |
|
|
FDCDDQ
104
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| – | -$207K | -43,502 | Closed |
|
105
AQR Capital Management
Greenwich,
Connecticut
| – | -$139K | -29,043 | Closed |
|
|
OAM
106
Oberweis Asset Management
Lisle,
Illinois
| – | -$114K | -24,000 | Closed |
|
107
Creative Planning
Overland Park,
Kansas
| – | -$88K | -18,350 | Closed |
|
108
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
| – | -$78K | -16,253 | Closed |
|
|
VF
109
Virtu Financial
New York
| – | -$54K | -11,374 | Closed |
|
|
AF
110
Allworth Financial
Folsom,
California
| – | -$2K | -500 | Closed |
|
|
KF
111
Krilogy Financial
St. Louis,
Missouri
| – | -$1K | -200 | Closed |
|
BCRX Hedge Fund Activity: Q2 2018 in Review
103 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q2 2018, worth a combined $501M — up 18% from $425M a quarter earlier.
Fund positioning in BCRX was balanced in Q2 2018: 10 funds opened new positions, 10 closed out, 25 added to existing stakes and 36 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $18.9M. The largest seller was Deerfield Management, cutting an estimated $7.17M.
- 103 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q2 2018, unchanged from Q1 2018.
- Funds reported $501M of BioCryst Pharmaceuticals stock for Q2 2018, up 18% quarter-over-quarter.
- 10 funds opened new BioCryst Pharmaceuticals positions in Q2 2018 and 10 closed out, a net change of 0 holders.
- The largest BioCryst Pharmaceuticals buyer in Q2 2018 was Janus Henderson Group, an estimated $18.9M added.
- The largest BioCryst Pharmaceuticals seller in Q2 2018 was Deerfield Management, an estimated $7.17M sold.
Based on aggregated 13F filings for Q2 2018.